Ulrich Brandt, theme Mitochondrial diseases received a NWO Top grant of € 780,000 for a project entitled: Molecular mechanism and regulation of energy conversion by mitochondrial complex I.
The complexes of oxidative phosphorylation are the major energy converters of aerobic cells that are also involved in multiple other cellular processes. Complex I (NADH:ubiquinone oxidoreductase) is the largest and most complicated respiratory chain enzyme. It is a major source of reactive oxygen species and in man prominently involved in inherited mitochondrial diseases, neurodegenerative disorders and aging. Despite its tremendous biomedical importance, there is large gap of knowledge, when it comes to the mechanism and regulation of mitochondrial complex I. The recently solved bacterial and mitochondrial X-ray structures launch a new phase in complex I research by finally providing the blueprints of this fascinating molecular machine that were desperately needed to unravel its intricate molecular mechanism. Our X-ray structure of mitochondrial complex I and our structure/function studies provided fundamental insights into the design and dynamics of the ubiquinone-binding pocket. It led us to propose an integrated mechanistic model for catalysis and regulation of complex I. Using this hypothesis as a starting point, we will elucidate the still enigmatic molecular mechanism of complex I and its poorly understood regulation by the so-called active/deactive (A/D) transition. Specifically we aim at defining the catalytic and regulatory sub-states of complex I and how they control the chemistry of ubiquinone intermediates by a combination of advanced, mutagenesis based structure/function analysis and structural analysis.
Specifically, we will work out in detail the “mechanics” of the conformational changes by which the charge induced reorganiza¬tion of the ubiquinone binding site leads to the generation of the power stroke transmitted into the membrane arm to drive proton pumping. To this end, we will probe the loop rearrangements within the ubiquinone binding pocket to decipher their workings during catalytic turnover and the A/D transition. Furthermore, we will define the structural features controlling the chemistry of ubiquinone in the different functional states of mitochondrial complex I. Finally, we aim at understanding, how the mechanism of energy conversion of complex I is controlled by the A/D transition at the molecular level.
We expect that at the end of the funding period we can present a refined and experimentally well supported molecular mechanism of energy conversion that integrates the different func¬tional modes of mitochondrial complex I. Although the focus of the proposed study is exclusively on fundamental research, the results will have broad biomedical impact, since complex I dysfunction has been implicated in numerous human pathologies, including inherited mitochondrial disease, M. Parkinson, M. Alzheimer, ischemia/ reperfusion injuries and biological ageing.
Related news items
Jong KNCV organizes a Pitch competition for PhD candidates13 August 2020
Are you a PhD candidate and would you like to win 500 euros with a pitch about your research? Young KNCV gives you that chance! During the KNCV Chemistry 2020 Evening on October 8th.read more
Collective invasion induced by autocrine purinergic loop through connexin-43 hemichannels13 August 2020
Peter Friedl and Paul Span show in Journal of Cell Biology that breastcancer cells release purines into the extracellular space via connexin-43 hemichannels to control collective invasion.read more
TP53 allelic state is critical for diagnostic and prognostic precision in blood cancer12 August 2020
An international study, in which Joop Jansen participated, shows that a double mutaton in TP53 gene deteriotes the prognosis of a rare form of blood cancer. If there is only one mutation or no mutation, then the prognosis is better.read more
BCG vaccine is safe with no increased risk of COVID-19 symptoms says Mihai Netea11 August 2020
The BCG vaccine has a general stimulatory effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.read more
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more